The department of pharmaceuticals (DoP) has overturned the National Pharmaceutical Pricing Authority (NPPA)'s decision on fixing the ceiling price of Superspas-RF injection manufactured by Karnal-based Nitin Lifesciences Ltd and has directed the NPPA not to consider this formulation as a scheduled formulation.

Earlier, the NPPA vide its notification S.O. No.945(E) dated 27.3.2014 issued under Drugs Price Control Order, 2013 (DPCO, 2013) had fixed the ceiling price of Superspas-RF injection.

Aggrieved by the notification, the Haryana-based Nitin Lifesciences Ltd filed a review application with the reviewing authority, DoP, against the fixation of ceiling price on Superspas-RF injection.

Personal hearing was granted to the petitioners by the DoP on 13.5.2014. The petitioners were represented by Umesh Sanghi, technical adviser, and Subhash Malhotra. On behalf of the NPPA, Manish Goswami, Deputy Director attended the hearing.

The issues involved in the review application have been examined based on the record note of discussions of the personal hearing and other documents on record. After examining the issue, the DoP directed the NPPA not to consider this formulation as a scheduled formulation.  “NPPA is directed not to consider subject formulation as a scheduled formulation,” the DoP in its order said.